메뉴 건너뛰기
Journal of Clinical Oncology
Volumn 34, Issue 16, 2016, Pages e151-e155
Intrathecal trastuzumab halts progression of CNS metastases in breast cancer
Author keywords

[No Author keywords available]
Indexed keywords

CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GADOLINIUM; LAPATINIB; MESSENGER RNA; TRASTUZUMAB; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;
EID: 84973370428     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.8894     Document Type: Article
Times cited : (34)
References (14)
  • 1
    • 0035869407 scopus 로고    scopus 로고
    • Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2
    • Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2. N Engl J Med 344:783-792, 2001
    • (2001) N Engl J Med , vol.344 , pp. 783-792
    • Slamon, D.J.1    Leyland-Jones, B.2    Shak, S.3
  • 2
    • 70449698237 scopus 로고    scopus 로고
    • Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases
    • Leyland-Jones B: Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 27:5278-5286, 2009
    • (2009) J Clin Oncol , vol.27 , pp. 5278-5286
    • Leyland-Jones, B.1
  • 3
    • 0346017700 scopus 로고    scopus 로고
    • Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel
    • Leyland-Jones B, Gelmon K, Ayoub JP, et al: Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 21:3965-3971, 2003
    • (2003) J Clin Oncol , vol.21 , pp. 3965-3971
    • Leyland-Jones, B.1    Gelmon, K.2    Ayoub, J.P.3
  • 4
    • 0032713216 scopus 로고    scopus 로고
    • Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
    • Tokuda Y, Watanabe T, Omuro Y, et al: Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Br J Cancer 81:1419-1425, 1999
    • (1999) Br J Cancer , vol.81 , pp. 1419-1425
    • Tokuda, Y.1    Watanabe, T.2    Omuro, Y.3
  • 6
    • 33744939239 scopus 로고    scopus 로고
    • Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer
    • Stemmler HJ, Schmitt M, Harbeck N, et al: Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol Rep 15:1373-1377, 2006
    • (2006) Oncol Rep , vol.15 , pp. 1373-1377
    • Stemmler, H.J.1    Schmitt, M.2    Harbeck, N.3
  • 7
    • 54949107844 scopus 로고    scopus 로고
    • High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer
    • Mir O, Ropert S, Alexandre J, et al: High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann Oncol 19:1978-1980, 2008
    • (2008) Ann Oncol , vol.19 , pp. 1978-1980
    • Mir, O.1    Ropert, S.2    Alexandre, J.3
  • 8
  • 9
    • 0035283233 scopus 로고    scopus 로고
    • Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier
    • Zhang Y, Pardridge WM: Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier. J Neuroimmunol 114:168-172, 2001
    • (2001) J Neuroimmunol , vol.114 , pp. 168-172
    • Zhang, Y.1    Pardridge, W.M.2
  • 10
    • 34548229364 scopus 로고    scopus 로고
    • FcRn: The neonatal Fc receptor comes of age
    • Roopenian DC, Akilesh S: FcRn: The neonatal Fc receptor comes of age. Nat Rev Immunol 7:715-725, 2007
    • (2007) Nat Rev Immunol , vol.7 , pp. 715-725
    • Roopenian, D.C.1    Akilesh, S.2
  • 11
    • 20144368709 scopus 로고    scopus 로고
    • Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration
    • Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al: Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 112:1048-1053, 2005
    • (2005) Ophthalmology , vol.112 , pp. 1048-1053
    • Rosenfeld, P.J.1    Schwartz, S.D.2    Blumenkranz, M.S.3
  • 12
    • 33749445317 scopus 로고    scopus 로고
    • Ranibizumab for neovascular age-related macular degeneration
    • Rosenfeld PJ, Brown DM, Heier JS, et al: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419-1431, 2006
    • (2006) N Engl J Med , vol.355 , pp. 1419-1431
    • Rosenfeld, P.J.1    Brown, D.M.2    Heier, J.S.3
  • 13
    • 78449305285 scopus 로고    scopus 로고
    • Safety and pharmacokinetic analysis of methotrexate administered directly into the fourth ventricle in a piglet model
    • Sandberg DI, Solano J, Petito CK, et al: Safety and pharmacokinetic analysis of methotrexate administered directly into the fourth ventricle in a piglet model. J Neurooncol 100:397-406, 2010
    • (2010) J Neurooncol , vol.100 , pp. 397-406
    • Sandberg, D.I.1    Solano, J.2    Petito, C.K.3
  • 14
    • 77949267675 scopus 로고    scopus 로고
    • Pharmacokinetic analysis of etoposide distribution after administration directly into the fourth ventricle in a piglet model
    • Sandberg DI, Crandall KM, Koru-Sengul T, et al: Pharmacokinetic analysis of etoposide distribution after administration directly into the fourth ventricle in a piglet model. J Neurooncol 97:25-32, 2010
    • (2010) J Neurooncol , vol.97 , pp. 25-32
    • Sandberg, D.I.1    Crandall, K.M.2    Koru-Sengul, T.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.